Are we altering the natural history of primary myelofibrosis?

Leukemia Research

Volumn 38, Issue 9, 2014, Pages 1004-1012

  Savona, Michael R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

JAK inhibitors; Myelofibrosis; Proinflammatory cytokines; Spleen volume; Targeted therapy

Indexed keywords

AB 0023; FEDRATINIB; FRESOLIMUMAB; GANDOTINIB; IMETELSTAT; JANUS KINASE; LESTAURTINIB; MOMELOTINIB; PACRITINIB; PANOBINOSTAT; PLACEBO; PRACINOSTAT; PRM 151; RECOMBINANT ALPHA INTERFERON; RECOMBINANT PROTEIN; RUXOLITINIB; SIMTUZUMAB; STAT PROTEIN; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY WEIGHT; CACHEXIA; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; HUMAN; INFLAMMATION; LABORATORY TEST; LUNG FIBROSIS; LYMPHATIC PARAMETERS; METABOLIC PARAMETERS; METABOLIC STATUS; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SPLEEN VOLUME; SPLENOMEGALY; SURVIVAL TIME; TREATMENT RESPONSE; WERNICKE ENCEPHALOPATHY;

JAK INHIBITORS; MYELOFIBROSIS; PROINFLAMMATORY CYTOKINES; SPLEEN VOLUME; TARGETED THERAPY;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84906934079     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.04.012     Document Type: Review

References (94)

1. Mascarenhas J., Mughal T.I., Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 2012, 19:4399-4413.
2. Vannucchi A.M. Management of myelofibrosis. Hematol Am Soc Hematol Educ Prog 2011, 2011:222-230.
3. Savona M., Ma Z., Debusk L., Chandra P., Liang S., Cooper R.S., Raefsky E., et al. Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis ASH Annual Meeting Abstracts. Blood 2013, 122:5266.
4. Abdel-Wahab O., Pardanani A., Bernard O.A., Finazzi G., Crispino J.D., Gisslinger H., et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol 2012, 87:562-568.
5. Mascarenhas J., Roper N., Chaurasia P., Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenet 2011, 2:197-212.
6. Cross N.C. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Prog 2011, 2011:208-214.
7. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
8. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
9. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
10. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
11. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
12. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
13. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
14. Mesa R.A., Gotlib J., Gupta V., Catalano J.V., Deininger M.W., Shields A.L., et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013, 31:1285-1292.
15. Harrison C.N., Mesa R.A., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Knoops L., et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013, 162:229-239.
16. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., Dipersio J.F., et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98:1865-1871.
17. Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., et al. on behalf of the COMFORT-II investigators Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013, 122:4047-4053.
18. Gupta V., Hari P., Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012, 120:1367-1379.
19. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
20. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
21. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
22. Gianelli U., Vener C., Bossi A., Cortinovis I., Iurlo A., Fracchiolla N.S., et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012, 25:1193-1202.
23. Lekovic D., Gotic M., Perunicic-Jovanovic M., Vidovic A., Bogdanovic A., Jankovic G., et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol 2014, 31:869.
24. Mesa R.A., Schwager S., Huang J., Pardanani A.D., Hussein K., Camoriano J., et al. Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 inhibitor era. Blood 2009, 114:3918.
25. Sulai N., Mengistu B., Gangat N., Hanson C.A., Ketterling R.P., Pardanani A., et al. Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value. Blood 2012, 120:2851.
26. Vannucchi A.M., Kantarjian H., Kiladjian J.-J., Gotlib J., Cervantes F., Mesa R.A., et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood 2013, 122:2820.
27. Vannucchi A.M., Lasho T.L., Guglielmelli P., Biamonte F., Pardanani A., Pereira A., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
28. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109:68-76.
29. Mesa R.A., Li C.Y., Ketterling R.P., Schroeder G.S., Knudson R.A., Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105:973-977.
30. Firmbach-Kraft I., Byers M., Shows T., Dalla-Favera R., Krolewski J.J. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990, 5:1329-1336.
31. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zürcher G., Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991, 11:2057-2065.
32. Harpur A.G., Andres A.C., Ziemiecki A., Aston R.R., Wilks A.F. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992, 7:1347-1353.
33. Rane S.G., Reddy E.P. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994, 9:2415-2423.
34. Neubauer H., Cumano A., Müller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
35. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
36. Witthuhn B.A., Quelle F.W., Silvennoinen O., Yi T., Tang B., Miura O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
37. Shuai K., Ziemiecki A., Wilks A.F., Harpur A.G., Sadowski H.B., Gilman M.Z., et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of JAK and STAT proteins. Nature 1993, 366:580-583.
38. Penta K., Sawyer S.T. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 1995, 270:31282-31287.
39. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013, 369:2379-2390.
40. Lundberg P., Karow A., Nienhold R., Looser R., Hao-Shen H., Nissen I., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014, 123:177-181.
41. Ferrer-Marín F., Bellosillo B., Martinez-Avilés L., Soler G., Carbonell P., Luengo-Gil G., et al. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing. J Hematol Oncol 2013, 6:68.
42. Anand S., Stedham F., Beer P., Gudgin E., Ortmann C.A., Bench A., et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118:177-181.
43. Vannucchi A.M., Guglielmelli P., Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009, 59:171-191.
44. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013, 369:2391-2405.
45. Passamonti F., Caramazza D., Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014, 370:1168-1169.
46. Abdel-Wahab O., Adli M., LaFave L.M., Gao J., Hricik T., Shih A.H., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
47. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., Dipersio J.F., et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013, 122:396.
48. Pardanani A., Laborde R.R., Lasho T.L., Finke C., Begna K., Al-Kali A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27:1322-1327.
49. Komrokji R.S., Wadleigh M., Seymour J.F., Roberts A.W., To L.B., Zhu H.J., et al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011, 118:282.
50. Talpaz M., Jamieson C., Gabrail N.Y., Lebedinsky C., Gao G., Liu F., et al. A Phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. Blood 2012, 120:2837.
51. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R.M., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
52. Santos F.P., Kantarjian H.M., Jain N., Manshouri T., Thomas D.A., Garcia-Manero G., et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136.
53. Verstovsek S., Mesa R.A., Rhoades S.K., Giles J.L.K., Pitou C., Jones E., et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2011, 118:2814.
54. Verstovsek S., Mesa R.A., Salama M.E., Giles J.L.K., Pitou C., Zimmermann A.H., et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013, 122:665.
55. Sanofi discontinues clinical development of investigational JAK2 agent fedratinib (SAR302503) [press release] 2013, Sanofi, Paris, France, [accessed 27.02.14]. http://m-en.sanofi.com/Images/34935_20131118_JAK-2-FEDRATINIB_en.pdf.
56. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
57. Scott H.R., McMillan D.C., Crilly A., McArdle C.S., Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996, 73:1560-1562.
58. Iwase S., Murakami T., Saito Y., Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 2004, 15:312-316.
59. Bach E., Nielsen R.R., Vendelbo M.H., Møller A.B., Jessen N., Buhl M., et al. Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. Diabetes 2013, 62:4023-4029.
60. Mesa R.A., Verstovsek S., Gupta V., Mascarenhas J., Atallah E., Sun W., et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. Blood 2012, 120:1733.
61. Hasselbalch H.C. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013, 24:133-145.
62. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132.
63. Argano S.A., Marasa L., Daniele E., Pitre V., Morello V., Lampasona G., et al. Experimental myelofibrosis. Problems related to histogenesis and to spontaneous and therapeutic reversibility of the lesions. Haematologica 1977, 62:590-602.
64. Inoue S., Limsuwan A., McQueen R. Spontaneous resolution of myelofibrosis and pancytopenia followed by the development of acute myeloid leukemia with an extramedullary mass. J Pediatr Hematol Oncol 1998, 20:268-270.
65. Kröger N., Kvasnicka M., Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair 2012, 5(Suppl. 1):S25.
66. Silver R.T., Vandris K., Goldman J.J. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011, 117:6669-6672.
67. Kvasnicka H.M., Thiele J., Bueso-Ramos C.E., Hou K., Cortes J.E., Kantarjian H.M., et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol 2013, 31(Suppl.):7030.
68. Kvasnicka H.M., Thiele J., Bueso-Ramos C.E., Sun W., Cortes J., Kantarjian H.M., et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013, 122:4055.
69. Wilkins B.S., Radia D., Woodley C., El Farhi S., Keohane C., Harrison C.N. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013, 98:1872-1876.
70. Santos F.P., Verstovsek S. What is next beyond Janus kinase 2 inhibitors for primary myelofibrosis?. Curr Opin Hematol 2013, 20:123-129.
71. V617F-driven disease. Clin Cancer Res 2013, 19:6230-6241.
72. Duffield J.S., Lupher M.L. P.R.M-151Jr. (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect 2010, 23:305-315.
73. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H.M., Oyasu M., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.
74. Passamonti F., Maffioli M., Cervantes F., Vannucchi A.M., Morra E., Barbui T., et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014, 123:1833-1835.
75. Tefferi A., Begna K., Laborde R.R., Patnaik M.M., Lasho T.L., Zblewski D., et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013, 122:662.
76. Chagraoui H., Komura E., Tulliez M., Giraudier S., Vainchenker W., Wendling F. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
77. Vannucchi A.M., Bianchi L., Paoletti F., Pancrazzi A., Torre E., Nishikawa M., et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis. Blood 2005, 105:3493-3501.
78. Trachtman H., Fervenza F.C., Gipson D.S., Heering P., Jayne D.R., Peters H., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79:1236-1243.
79. Dillingh M.R., van den Blink B., Moerland M., van Dongen M.G., Levi M., Kleinjan A., et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013, 26:672-676.
80. Mascarenhas J., Lu M., Li T., Petersen B., Hochman T., Najfeld V., et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013, 161:68-75.
81. Quintás-Cardama A., Kantarjian H., Estrov Z., Borthakur G., Cortes J., Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 2012, 36:1124-1127.
82. Nguyen H.M., Kiladjian J.J. Is there a role for the use of IFN-alpha in primary myelofibrosis. Hematol Am Soc Hematol Educ Prog 2012, 2012:567-570.
83. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.
84. Wehrle J., Seeger T.S., Schwemmers S., Pfeifer D., Bulashevska A., Pahl H.L. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica 2013, 98:1073-1080.
85. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 2013, 161:508-516.
86. Ha J.S., Kim Y.K., Jung S.I., Jung H.R., Chung I.S. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 2012, 32:385-391.
87. Pich A., Riera L., Beggiato E., Nicolino B., Godio L., Campisi P., et al. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia. J Clin Pathol 2012, 65:953-955.
88. Gebauer N., Bernard V., Gebauer W., Feller A.C., Merz H. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis. Acta Haematol 2013, 129:251-256.
89. Stauffer Larsen T., Iversen K.F., Hansen E., Mathiasen A.B., Marcher C., Frederiksen M., et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013, 37:1041-1045.
90. Lange T., Edelmann A., Siebolts U., Krahl R., Nehring C., Jakel N., et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013, 98:722-728.
91. Takahashi K., Patel K.P., Kantarjian H., Luthra R., Pierce S., Cortes J., et al. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 2013, 122:3784-3786.
92. Alvarez-Larran A., Bellosillo B., Pereira A., Kerguelen A., Hernandez-Boluda J.C., Martinez-Aviles L., et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 2014.
93. Constantinescu S.N., Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?. Hematol Am Soc Hematol Educ Prog 2012, 2012:553-560.
94. Tefferi A., Cervantes F., Mesa R., Passamonti F., Verstovsek S., Vannucchi A.M., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013, 122:1395-1398.